As the country continues to deal with the fallout of the infamous Jeffery Epstein files, The Root is taking a closer look at ...

Novavax's H5N1 avian pandemic influenza vaccine candidate demonstrates immunogenicity in preclinical study: Gaithersburg, Maryland Friday, July 25, 2025, 15:00 Hrs [IST] Novavax, ...

Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

A series of recent changes could have significant implications for how Americans receive and pay for their shots.

The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...